Difference between revisions of "20.109(F20):Journal club presentation"
From Course Wiki
Noreen Lyell (Talk | contribs) |
Noreen Lyell (Talk | contribs) |
||
Line 6: | Line 6: | ||
FIND ARTICLES FOR CATEGORIES: MALARIA BIOLOGY, SMM STUDIES, DRUG DISCOVERY RESEARCH | FIND ARTICLES FOR CATEGORIES: MALARIA BIOLOGY, SMM STUDIES, DRUG DISCOVERY RESEARCH | ||
− | + | '''P. falciparum'' biology''' | |
'''Malaria drug discovery''' | '''Malaria drug discovery''' | ||
Brill, E. et al. “Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.” (2017) Oncotarget. PMID:29158830 | Brill, E. et al. “Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.” (2017) Oncotarget. PMID:29158830 |
Revision as of 23:47, 24 July 2020
FIND ARTICLES FOR CATEGORIES: MALARIA BIOLOGY, SMM STUDIES, DRUG DISCOVERY RESEARCH
P. falciparum biology
Malaria drug discovery
Brill, E. et al. “Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.” (2017) Oncotarget. PMID:29158830